KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Common Equity (2020 - 2025)

Historic Common Equity for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to $1.0 billion.

  • Recursion Pharmaceuticals' Common Equity rose 9958.63% to $1.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year increase of 9958.63%. This contributed to the annual value of $1.0 billion for FY2024, which is 12328.48% up from last year.
  • Per Recursion Pharmaceuticals' latest filing, its Common Equity stood at $1.0 billion for Q3 2025, which was up 9958.63% from $919.1 million recorded in Q2 2025.
  • Recursion Pharmaceuticals' Common Equity's 5-year high stood at $1.0 billion during Q3 2025, with a 5-year trough of -$233.0 million in Q1 2021.
  • Over the past 5 years, Recursion Pharmaceuticals' median Common Equity value was $493.6 million (recorded in 2022), while the average stood at $558.0 million.
  • In the last 5 years, Recursion Pharmaceuticals' Common Equity soared by 36319.29% in 2021 and then tumbled by 3522.32% in 2022.
  • Recursion Pharmaceuticals' Common Equity (Quarter) stood at $542.9 million in 2021, then decreased by 10.52% to $485.8 million in 2022, then dropped by 4.6% to $463.4 million in 2023, then soared by 123.28% to $1.0 billion in 2024, then increased by 1.18% to $1.0 billion in 2025.
  • Its Common Equity stands at $1.0 billion for Q3 2025, versus $919.1 million for Q2 2025 and $933.9 million for Q1 2025.